Alimetrix® Covid-19 Tests
SARS-CoV-2 PCR Test
The Alimetrix SARS-CoV-2 RT-PCR Assay is an EUA approved (EUA202074) molecular RT-PCR assay for the qualitative detection of nucleic acid from SARS-CoV-2 (Covid-19). Our methodology makes it possible to selectively amplify the viral genome and greatly increase the sensitivity of the assay. Tests are performed on mid turbinate nasal specimens from individuals suspected to have an active infection. Using a series of three identification probes we are able to discern CoV-2 from other coronaviruses. This results in a high degree of specificity with fewer false positive results. Our test will help diagnose those currently infected with CoV-2 and actively shedding the virus. These individuals are considered infectious to others at this stage of their illness.
The Alimetrix® SARS-CoV-2 RT-PCR Fact Sheets
CoV19 SeroTest
Coming soon
Developed by Alimetrix, the new SARS-CoV-2 (COVID-19) serological test will provide physicians with meaningful CoV-2 immune status information. This is helpful in getting the full scope of an individual’s past exposure to the virus, in assessing the immunological status to a current infection, and to gauging the level and magnitude of the immune response post-infection or post-vaccination. The Alimetrix test is highly sensitive, with a high degree of specificity. Our test is also able to detect immunoglobulin class and provides quantitative results.
Of the seven known coronaviruses that cause infections in humans, four typically cause common non-life threatening upper respiratory infections. The Alimetrix test is designed to identify and distinguish between the seven coronaviruses with a high degree of specificity to insure that the results are distinctly attributable to CoV-2. The Alimetrix test is fluorescence based, which is approximately 10 times more sensitive than most quick-test lateral flow CoV-2 assays with colorimetric readouts.
The Alimetrix test is designed to produce quantitative results which will help gauge the magnitude of the immune response both post-infection and post-vaccination. This will be extremely beneficial in older adults with waning immune response and those who are immunocompromised or immunosuppressed.